Ozempic Users Are Skimping Out on Exercise, Study Finds
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A recent study finds that physical activity declines among individuals using GLP-1 medications for obesity. Coverage from Healio, Medical Xpress, and Neuroscience News highlights that patients taking these drugs are moving less, with ScienceDaily reporting similar trends for those on weight loss medications like Ozempic.
The Times and Yahoo Creators focus on the implications of this reduced movement, specifically the potential for muscle loss. Morningstar and The Times explore strategies for training and preserving muscle mass while using these treatments, though coverage does not yet specify the exact mechanisms driving the behavior change.
Case Western Reserve University features expert analysis from Ian Neeland regarding the health effects of GLP-1 drugs. Healthline examines the reasons users are less likely to exercise.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 150d ago.
Quick answers
What does the new study reveal?
The study finds that physical activity and spontaneous movement decline in patients after they start GLP-1 obesity treatments.
What is the primary health concern noted?
Coverage emphasizes the risk of muscle loss associated with reduced exercise while taking GLP-1 weight loss drugs.
Are there solutions being discussed?
Outlets like The Times and Morningstar provide guidance on how to train and lose weight without losing muscle during treatment.
Coverage (14)
- Exercise declined in patients with obesity after starting a GLP-1 Healio · 153d ago
- The GLP-1 workout: how to train if you’re on fat jabs The Times · 153d ago
- Physical activity declines after starting GLP-1 obesity treatments News-Medical · 153d ago
- People taking GLP-1 weight loss drugs like Ozempic started moving less ScienceDaily · 153d ago
- People taking GLP-1 weight loss drugs like Ozempic started moving less ScienceDaily · 153d ago
- Physical Activity Declines Among Individuals Using GLP-1 Medications, Study Finds Bioengineer.org · 153d ago
- GLP-1 Therapies Silence Spontaneous Physical Activity Neuroscience News · 153d ago
- GLP-1 Weight Loss Can Mean Muscle Loss Yahoo Creators · 153d ago
- Study finds exercise decreases among people taking GLP-1 medication Medical Xpress · 153d ago
- The GLP-1 Era: How To Lose Weight Without Losing Muscle Morningstar · 153d ago
- Medicine's Ian Neeland explores the health effects of GLP-1 drugs Case Western Reserve University · 153d ago
- The 20-minute Ozempic workout The Times · 153d ago
- Ozempic, Wegovy: Why People Using GLP-1s Are Less Likely to Exercise Healthline · 153d ago
- Ozempic Users Are Skimping Out on Exercise, Study Finds Gizmodo · 153d ago
Topics
Related trends
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.